Related Experiment Video
Updated: Jul 5, 2025
03:47
Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
Published on: July 12, 2024
793
Health equity in heart failure.
Aishwarya Vijay1, Clyde W Yancy1
1Department of Internal Medicine, Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, IL, United States of America.
Progress in Cardiovascular Diseases
|January 12, 2024
Summary
Achieving health equity in heart failure (HF) treatment is crucial. Addressing disparities in guideline-directed medical therapies (GDMT) ensures all patients with reduced ejection fraction (HFrEF) benefit from advanced HF care.
Area of Science:
- Cardiology
- Public Health
- Health Equity
Background:
- Heart failure with reduced ejection fraction (HFrEF) treatment has advanced significantly with evidence-based therapies.
- The "four pillars" of HFrEF therapy include beta blockers, RAAS inhibitors, MRAs, and SGLT2 inhibitors, improving survival and quality of life.
- Despite proven benefits, guideline-directed medical therapies (GDMT) for HFrEF are underutilized, especially in minority populations, creating significant health disparities.
Purpose of the Study:
- To highlight the difference between health equality and health equity in heart failure care.
- To discuss the need for equitable treatment in HFrEF, ensuring all individuals benefit from therapeutic advancements.
- To propose strategies for reducing and eliminating health disparities in HFrEF management.
Main Methods:
- Review of current evidence-based medical therapies for HFrEF.
- Analysis of health disparities in the application of GDMT.
- Discussion of socioeconomic determinants and racism as threats to public health in HF.
- Proposal for combining ethical principles with GDMT to personalize HFrEF treatment.
Main Results:
- Significant disparities exist in the utilization of effective HFrEF treatments among vulnerable populations.
- Socioeconomic factors and racism are identified as key determinants contributing to these health inequities.
- The 2022 AHA/ACC/HFSA guidelines emphasize addressing HF disparities.
Conclusions:
- Achieving true equity in heart failure treatment requires addressing systemic disparities.
- Personalized treatment strategies, integrating ethical considerations with GDMT, are essential for equitable HFrEF care.
- Eliminating disparities in HFrEF treatment is critical to ensure all patients receive optimal cardiovascular benefits.
More Related Videos
Related Concept Videos
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:26Imbalances in Cardiac Output
1.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
01:22Heart Failure Drugs: Diuretics
384
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
384
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
432
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
432
01:22Heart Failure Drugs: β-Blockers
341
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
341
01:26Heart Failure Drugs: Inotropic Agents
591
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
591